| Autor: |
Wayne C. Widdison, Ravi V.J. Chari, John M. Lambert, Hans K. Erickson, Qifeng Qiu, Rui Wu, Paulin Salomon, Rabih Gabriel, Anna Skaletskaya, Juliet A. Costoplus, Karen Veale, Leanne Lanieri, Jennifer A. Coccia, Gregory E. Jones, Ling Dong, Nathan Fishkin, E. Erica Hong, Katharine C. Lai, Yelena V. Kovtun, Jose Ponte, Yulius Y. Setiady, Rajeeva Singh |
| Rok vydání: |
2023 |
| Popis: |
Supplementary Figures (S1-S4). Supplementary Figure S1: In vitro cytotoxic activities of tetraglycyl (Gly4), triglycyl (Gly3), diglycyl (Gly2), and valine-citrulline-glycine (VCG)-linked anti-EGFR ADCs and a triglycyl-linked non-binding antibody ADC in PC-9, Ca9-22, HSC-2, H1975, A-431, and OSC-19 cells (3-4 DAR ADCs). Supplementary Figure S2: In vitro cytotoxic activities of anti-EpCAM CX and SMCC ADCs toward a low EpCAM antigen-expressing cell line, RPMI 8226 (~50,000 EpCAM per cell). The CX ADCs tested included a conjugate with a typical payload number (3.9 maytansinoid molecules per antibody molecule; 3.9 DAR) and conjugates with high payload numbers (8 and 9.6 DAR). The SMCC ADC had a typical payload number (4.3 DAR). Supplementary Figure S3: Binding-competition ELISA of catabolites of CX ADC (DM-CX1 and DM-CX2) and SMCC ADC (lysine-SMCC-DM1): inhibition by catabolites toward binding of anti-maytansine antibody to immobilized BSA-maytansinoid conjugate. Supplementary Figure S4: Test of bystander cytotoxic activity of anti-EGFR-CX-DM1 or SPDB-DM4 conjugate in mixed culture of EGFR-positive (Ca9-22) and EGFR-negative (Ramos) cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
